• Rare response to radiotherapy produces dramatic anti-cancer effect
• Noxopharm examining potential to convert rare event into common event
• Pre-clinical project underway to define mechanism of action • Two clinical studies to commence in 2017.
Sydney, 3 March 2017: Recent patent filings mean Noxopharm (ASX:NOX) now is able to announce details of a major commitment to an R&D program involving a rare phenomenon encountered in cancer patients undergoing radiotherapy. The phenomenon is known as an ‘abscopal response’ and essentially means the unexpected disappearance of all cancers in the body following exposure of only a limited number of those cancers to radiotherapy.
For further information please download PDF attached:
Download this document
